Erasca (ERAS) Interest & Investment Income (2020 - 2026)
Erasca (ERAS) reported Interest & Investment Income of $4.4 million for Q1 2026, down 6.14% on a YoY basis from $4.7 million in Q1 2025, and up 24.76% quarter-over-quarter from $3.6 million in Q4 2025.
Erasca (ERAS) Interest & Investment Income (2020 - 2026) Analysis & Trends
Erasca has reported Interest & Investment Income for 7 years, with the latest figure at $4.4 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 6.14% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (down 22.06% YoY), and the FY2025 full-year result was $16.6 million, down 17.35% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $4.4 million, up from $3.6 million in the prior quarter.
- The five-year high for Interest & Investment Income was $5.9 million in Q3 2024, with the low at $114000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $3.7 million across 5 years, with a median of $4.2 million in 2023.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 3497.5% — and 2025, when it sank 32.5%.
- Erasca's Interest & Investment Income stood at $2.9 million in 2022, then surged by 47.26% to $4.2 million in 2023, then gained by 24.66% to $5.3 million in 2024, then plunged by 32.5% to $3.6 million in 2025, then advanced by 24.76% to $4.4 million in 2026.
- The last three Interest & Investment Income figures came in at $4.4 million (Q1 2026), $3.6 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -14.79 Mn |
| 10 | Erasca | 4.28 Bn | 4.03 Bn | - | 4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 3.57 Mn |
| Sep 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 4.33 Mn |
| Mar 31, 2025 | 4.74 Mn |
| Dec 31, 2024 | 5.28 Mn |
| Sep 30, 2024 | 5.87 Mn |
| Jun 30, 2024 | 5.04 Mn |
| Mar 31, 2024 | 3.90 Mn |
| Dec 31, 2023 | 4.24 Mn |
| Sep 30, 2023 | 4.35 Mn |
| Jun 30, 2023 | 4.25 Mn |
| Mar 31, 2023 | 3.88 Mn |
| Dec 31, 2022 | 2.88 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Jun 30, 2022 | 388,000.00 |
| Mar 31, 2022 | 114,000.00 |
| Dec 31, 2021 | 80,000.00 |
| Sep 30, 2021 | 49,000.00 |
| Jun 30, 2021 | 31,000.00 |